Interestingly, DDIT4 has been identified as a prognosis marker and highly expressed in pancreatic tumors (Pinto et al., 2017), thus prompting the investigation into whether DDIT4 inhibition might be the triggering mechanism of action and thus serve as a predictive biomarker for CK21 sensitivity. The gene discussed is DDIT4; the disease is pancreatic neoplasm.